US Stocks
/
Cullinan Therapeutics, Inc. Share Price

Cullinan Therapeutics, Inc. Share Price

NASDAQ: CGEM | Small Cap
$15.53
+$0.03 (0.19%) Last updated on 10 Oct, 2026 | 01:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Cullinan Therapeutics, Inc. Stock Performance

Open
$15.34
Prev. Close
$15.50
Circuit Range
N/A
Day Range
$15.31 - $15.92
Year Range
$6.52 - $23.16
Volume
31,262
Average Traded
$15.55

Cullinan Therapeutics, Inc. Share Price Today

As of 10 October 2026, Cullinan Therapeutics, Inc.'s share price is $15.53. The stock opened at $15.34, compared to its previous close of $15.50. During today's trading session, Cullinan Therapeutics, Inc.'s share price traded between $15.31 and $15.92, with an average price of $15.62. Over the past 52 weeks, the stock has recorded a high of $23.16 and a low of $6.52. In terms of performance, Cullinan Therapeutics, Inc.'s share price has risen by 19.10% over the last six months and is up 79.12% on a year-on-year basis.

Cullinan Therapeutics, Inc. Share Price Chart

$15.31$15.92
L
Show Current Price
H

Cullinan Therapeutics, Inc. Stock Fundamentals & Key Indicators

Market Cap
$917.05M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-2.78
Revenue (TTM)
$0.00
Return On Equity (TTM)
-55.58%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-6.11%

Cullinan Therapeutics, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$50.61-$29.05-$45.49-$53.70
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A42.60%-56.59%-18.05%

Cullinan Therapeutics, Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$0.00$0.00
Net Profit$111.21-$133.45-$149.39-$198.21
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-220.00%-11.94%-32.68%

About Cullinan Therapeutics, Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Cullinan Therapeutics, Inc. Historical Returns

MonthOpenCloseChange %
Oct 2026
$15.21
$15.51
+0.98%
Sep 2026
$21.73
$15.36
-31.85%
Aug 2026
$16.50
$22.54
+36.61%
Jul 2026
$18.05
$16.50
-9.39%
Jun 2026
$15.96
$18.21
+10.80%
May 2026
$13.10
$16.43
+26.04%
Apr 2026
$14.43
$13.04
-8.23%
Mar 2026
$15.25
$14.21
-8.32%
Feb 2026
$12.40
$15.50
+29.60%
Jan 2026
$10.49
$11.96
+15.78%
Dec 2025
$11.33
$10.33
-8.95%
Nov 2025
$8.61
$11.35
+30.85%

CGEM Share Price FAQs

What is Cullinan Therapeutics, Inc. share price today?

chevron-up
Cullinan Therapeutics, Inc. share price today is $15.53 as on October 10, 2026 at 1:29 am IST.

What is the 52 week high and 52 week low of Cullinan Therapeutics, Inc. stock?

chevron-up
The 52 week high of Cullinan Therapeutics, Inc. stock is $23.16, while the 52 week low is $6.52 as of 10 Oct '26.

What is CGEM's market capitalisation today?

chevron-up
CGEM market capitalisation is $917.05M as of October 10, 2026, at 5:17 am IST.

What is CGEM's net income for the last quarter?

chevron-up
CGEM's net income for the last quarter is -53.70B USD.

What is the 5 year returns of CGEM?

chevron-up
The 5 year returns of CGEM is -30.20% as on 10 Oct '26.

What is the high & low stock price of CGEM today?

chevron-up
CGEM stock price hit a high of $15.92 and low of $15.31 as of 10 Oct '26.

Can I buy CGEM shares in India?

chevron-up
Yes. You can buy CGEM in India by opening an international trading account.